Steatosis and steatohepatitis in diabetic patient;Steatóza a steatohepatitida u diabetika

Vnitrni Lekarstvi

Volumn 57, Issue 4, 2011, Pages 364-367

  Hůlek, Petr ^a   Dresslerova I ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

NAFLD; NASH; Therapy of NAFLD; Therapy of NASH

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; INSULIN SENSITIZING AGENT; OXIDIZING AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ALCOHOL CONSUMPTION; ARTICLE; CELL DAMAGE; CLINICAL FEATURE; DEATH; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE LIVER DISEASE; FATTY LIVER; HISTOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS;

EID: 79955890597     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sundaram V, Northup G, Nadkarmi M et al. Metabolic syndrome is a major risk factor for NAFLD among patients with non-insulin dependent diabetes mellitus. Gastroenterology 2006; 130: A-824.
2. Sobhonslidsuk A, Jongjirasiri S, Wisedopas N et al. Waist Circumference as a determinant of visceral fat in NASH. Gastroenterology 2006; 130: A-820.
3. Younossi Z, Baranova A, Ad N et al. Serum adiponectin and resistin in NAFLD and arteriosclerosis. Gastroenterology 2006; 130: A-828.
4. Ibdah JA, Zhao Y, Chan TO et al. Development of NAFLD in mice heterozygous for mitochondrial trifunctional protein is associated with reduced activation of the PI3K/AKT signaling pathway. Gastroenterology 2006; 130: A762.
5. Treiber G, Weigt J, Kolfenbach S et al. The role of bacterial overgrowth in patients with NAFLD. Gastroenterology 2006; 130 (4 Suppl 2): A-823.
6. Jacqueminet S, Morra R, Munteanu M et al. Screening for advanced fibrosis using non-invasive biomarkers (Fibrotest-Fibrosure) in diabetic patients. Gastroenterology 2006; 130: A-822.
7. Suzuki A, Muto A, Okada T et al. Aminotransferase levels and ultrasonography evidence of fatty liver in patients with NAFLD change over time reflecting changes in body weight: A 3-year follow-up study. Gastroenterology 2006; 130: A-820.
8. Wieckowska A, Zein N, Yerian L et al. Detection of caspase activity in the blood of patients NAFLD as a novel biomarker of disease severity. Gastroenterology 2006; 130: A-749.
9. Shirin H, Aeed V, Sorin M et al. Utility of 13C-methacetin breath test in the evaluation of the extent of hepatic injury in an animal model. Gastroenterology 2006; 130: A-828.
10. Urita Y, Ishihara S, Arai K et al. [1-13C]-acetate breath test reveals impaired acetate metabolism in patients with fatty liver diseases. Gastroenterology 2006; 130: A-594.
11. Fukuzawa Y, Ohashi T, Matsumati E et al. Efficacy of non-invasive hepatic fibrosis quantification by liver elasticity measurement in nonalcoholic steatohepatitis (NASH) - comparison of ultrasonic transient elastography and histopathological diagnosis. Gastroenterology 2006; 130: A-79.
12. Kelleher TB, MacFarlane C, de Ledinghen V et al. Risk factors and hepatic elastography (Fibroscan) in the prediction of hepatic fibrosis in NASH. Gastroenterology 2006; 130: A768.
13. Munteanu M, Ngo Y, De Torres M et al. Three-dimensional and metabolic variability of Fibroscan (transient elastography) measures in healthy volunteers. Gastroenterology 2006; 130: A-768.
14. Larson S, Bowers S, Pulcini J et al. Histopathologic variability between the right and left lobe of the liver in obese patients undergoing bypass surgery. Gastroenterology 2006; 130: A-768.
15. Wintle ME, Nielsen L, Guan X et al. Exenatide reduced weight and decreased elevated hepatic alanine transaminase (ALT) in patients with type 2 diabetes: 82-week interim analysis. Gastroenterology 2006; 130: A-822.
16. Inoue M, Tazuma S, Hyogo S et al. Pravastatin, a HMG-CoA reductase inhibitor, attenuates hepatic oxidative stress to retard liver fibrogenesis of NAFLD in an in vivo study: An evidence for therapeutic potential of statin on NASH. Gastroenterology 2006; 130: A-828.
17. Merat S, Aduli M, Kazemi R et al. Changes in liver histology after one year of treatment with probucol in NASH. Gastroenterology 2006; 130: A-595.
18. Stefano JT, Oliveira C, Lima V et al. Protective effect of Yo Jyo Hen Shi Ko (YHK) in NASH in ob/ob mice: increased PPAR-alpha gene expression. Gastroenterology 2006; 130: A-827.
19. Dohmen T, Ohshima S, Orie Y et al. Cell protective function of epimorphin against oxidative stress caused by hydrogen peroxide. Gastroenterology 2006; 130: A-825.
20. Duma DG, Ozdemir F, Birben E et al. Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with NASH. Gastroenterology 2006; 130: A-828.
21. Yu J, Chu E, Chan H et al. Lipoprotein lipase activator NO-1886 ameliorates the severity of dietary steatohepatitis in mice. Gastroenterology 2006; 130: A-825.
22. Shields WW, Thomson KE, Grice GA. The effect of metformin and standard therapy versus standard therapy alone in non-diabetic patients with insulin resistence and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009; 2: 157-163.
23. Gastalldelli A, Harrison S, Belfort-Aguiar R. Pioglitazone in the treatment of NASH: The role of adiponectin. Aliment Pharmacol Ther 2010; 32; 769-775.
24. Sanyal A, Chalasani N, Kowdley K et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362; 1675-1685.